PYXS News and Press, Pyxis Oncology Inc.

BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a...

2024-04-12 17:05:37 ET Gainers: Applied Optoelectronics ( AAOI ) +5% . Eliem Therapeutics ( ELYM ) +4% . Infinera Corporation ( INFN ) +4% . Harrow ( HROW ) +4% . Health Catalyst ( HCAT ) +4% . Losers: Eagle Pharmaceutica...

2024-03-28 00:10:26 ET Summary Pyxis Oncology is developing antibodies and antibody-drug conjugates for various tumor types. Initial data from the phase 1 trials of PYX-106 and PYX-201 are now expected in H2'24 and fall 2024 respectively. PYXS raised $50M in gross proceeds wit...

2024-03-27 17:44:47 ET More on Pyxis Oncology Pyxis Oncology: Making A Bold Acquisition Move, But It's Not A Convincing Thesis Pyxis Oncology gets $8M payment for sale of royalty rights Read the full article on Seeking Alpha For further details see: Pyxis...

2024-03-27 07:43:03 ET More on Pyxis Oncology Pyxis Oncology: Making A Bold Acquisition Move, But It's Not A Convincing Thesis Pyxis Oncology stock rises as it looks to raise $50M through a private placement Seeking Alpha’s Quant Rating on Pyxis Oncology ...

Non-dilutive funding to support development of first-in-concept lead Antibody-Drug Conjugate (ADC) asset, PYX-201 Pyxis Oncology retains rights to three other antibodies in development by Apexigen’s licensees discovered through the APXiMAB platform BOSTON, March 27, 2024 (GLOBE NEW...

2024-03-21 11:32:38 ET More on Pyxis Oncology Pyxis Oncology: Making A Bold Acquisition Move, But It's Not A Convincing Thesis Pyxis Oncology stock rises as it looks to raise $50M through a private placement Read the full article on Seeking Alpha For further ...

2024-03-21 10:12:15 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Johnson & Johnson, Boston Scientific least shorted stocks in S&...

2024-03-21 08:43:23 ET Losers: Destination XL Group DXLG -16% after Q4 earnings release . Tourmaline Bio ( TRML ) -30% . Apyx Medical Corp APYX -17% after Q4 earnings release . Five Below FIVE -12% after Q4 earnings release . Designer Br...

PYX-201 Phase 1 Part 1 trial progressing with initial data expected in the fall of 2024 PYX-106 Phase 1 trial progressing with initial data expected 2H 2024 Completed $50 million private placement Expected cash runway into 2H 2026 BOSTON, March 21, 2024 (GLOBE NEWS...